Xiumin Xu from Pembroke Pines, FL

Name / Title

Company / Classification

Phones & Addresses

Xiumin Xu
Managing

A/X BIOTECH LLC

7305 SW 129 St, Miami, FL 33156
7305 SW 129, Miami, FL 33156

Xiumin Xu
Principal, Manager

New Bright Star Trading, LLC
Whol Nondurable Goods

233 NE 14 Ave, Golden Isles, FL 33009
3291 W Sunrise Blvd, Fort Lauderdale, FL 33311

Xiumin Xu
President, Secretary

Arco Global Corporation

7305 SW 129 St, Miami, FL 33156

Molecular Dissection Of Cellular Responses To Alloantigen Or Autoantigen In Graft Rejection And Autoimmune Disease
view source
US Patent:

20060263343, Nov 23, 2006
Filed:

May 15, 2006
Appl. No.:

11/433776
Inventors:

Norma Kenyon - Miami FL, US
Cynthia Healy - Miami FL, US
Steven Koester - Pembroke Pines FL, US
Xiumin Xu - Miami FL, US
International Classification:

C12Q 1/68
G01N 33/567
A61K 48/00
A61K 39/395
A61K 31/573
A61K 31/7048
A61K 31/4745
G01N 33/53
A61K 39/00
US Classification:

424093210, 424184100, 435006000, 435007200, 424155100, 514028000, 514171000
Abstract:

An antigen-specific T-cell response to alloantigen, tissue-specific antigen (e.g., islet antigen or other autoantigens involved in autoimmune disease), or self (or host) antigen is detected at an early stage of graft rejection or recurrent autoimmunity. An increase in cytotoxic lymphocyte gene (CLG) expression in peripheral blood is a risk factor for development of deleterious immune responses, which may be confirmed by functional assays. For example, the distinction between production of regulatory or inflammatory cytokines by T cells may dissect the type of immune response which is being induced: the survival of transplanted islet cells used to treat type 1 diabetes may be monitored, loss of the transplant by graft rejection (i.e., an alloantigen target) may be distinguished from autoimmune disease (i.e., a self or host antigen target).

Xiumin Xu